Vadimezan (DMXAA) is a vascular disrupting agents (VDA) and a competitive inhibitor of DT-diaphorase with a Ki of 20 μM and an IC50 of 62.5 μM in a cell-free assay. DMXAA (Vadimezan) is also a STING agonist with potential antitumor activity. DMXAA (Vadimezan) can effectively induce the expression of IFN-β and TNF-α in vitro, but has a relatively low effect on TNF-α. DMXAA (Vadimezan) has antiviral activity. Phase 3.

 

Brand: BCM

 

Target: Influenza Virus; VDA; STING; IFNAR

 

Signaling Pathways: Angiogenesis; Immunology/Inflammation; Microbiology/Virology

 

In Vitro: In DLD-1 human colon carcinoma cells, DMXAA inhibits DT-diaphorase activity without significant effects on the activity of cytochrome b5 reductase and cytochrome P450 reductase. Combination of menadione and DMXAA leads to an increase in the antiproliferative activity of DLD-1 cells. DMXAA, as an antiviral agent, inhibits VSV-induced cytotoxicity and influenza virus replication in RAW 264.7 macrophages. A recent study shows that DMXAA has non-immune-mediated inhibitory effects against several kinase members of VEGFR (vascular endothelial growth factor receptor), such as VEGFR2 signalling in human umbilical vein endothelial cells.

 

Melting Point: 259-261 °C

 

Boiling Point: 520.9±50.0 °C(Predicted)

 

Vapour Pressure: 0Pa at 20℃

 

pKa: 4.21±0.10(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water.

 

GHS: GHS07, GHS09

 

Isomeric SMILES: CC1=C(C2=C(C=C1)C(=O)C3=CC=CC(=C3O2)CC(=O)O)C  

 

InChIKey: XGOYIMQSIKSOBS-UHFFFAOYSA-N  

 

InChI: InChI=1S/C17H14O4/c1-9-6-7-13-15(20)12-5-3-4-11(8-14(18)19)17(12)21-16(13)10(9)2/h3-7H,8H2,1-2H3,(H,18,19)

 

Attribute
[CAS No.]	117570-53-3
[EINECS]	700-141-4
[Formula]	C17H14O4
[Molecular]	282.295
[Chem Name]	2-(5,6-dimethyl-9-oxoxanthen-4-yl)acetic acid
[Synonym]	DMXAA; Vadimezan
[Storage]	Sealed in dry, 2-8°C
[Form]	Light Brown Powder

Goods Tag